insights_auto
Why is LSTA down 5,76%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
0,98 $
arrow_downward
-5,76%(-0,060) 1D
0,96 $
arrow_downward
-2,00% (-0,020)bedtimeAfter hours
Closed: 18 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
1,05 $
High
1,10 $
Low
0,89 $
Mkt. cap
10,59 մլն
Avg. vol.
139,22 հզր
Volume
222,09 հզր
52-wk high
5,06 $
52-wk low
0,89 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
1,05 $
High
1,10 $
Low
0,89 $
Mkt. cap
10,59 մլն
Avg. vol.
139,22 հզր
Volume
222,09 հզր
52-wk high
5,06 $
52-wk low
0,89 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
BeInCrypto
·
1 ժամ առաջ
S&P 500 Breaks Critical Support: Is a Bigger Stock Market Crash Coming?
FXStreet
·
5 ժամ առաջ
Dow Jones Industrial Average drops as UnitedHealth and Nvidia fall
BigGo Finance
·
9 ժամ առաջ
S&P 500's Shiller P/E Tops 40 Again, Echoing Dot-Com Era Valuations
Traders Union
·
1 ժամ առաջ
S&P 500 dips below 200-day average after long streak, Ryan Detrick notes
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com